Dr Dominique Trudel, M.D., Ph. D., FRCPC
Pathologist, clinical assistant professor, researcher (CRCHUM)
Pathology and Cellular Biology, University of Montreal
Institut du cancer de Montréal, Montreal University and CRCHUM
2004 M.Sc., Université Laval
2005 Medicine, Université Laval
2011 Residency (FRCPC), Anatomic pathology, Université Laval
2013 Clinician-Scientists in Molecular Oncologic Pathology, University Health Network, Toronto, Canada
2014 Ph.D., eperimental medicine, Université Laval
2008-2011 FRQS Doctoral Training for Applicants with a Professional Degree
2015-2019 FRQS Research scholars: Junior 1
2015-2017 (PI) Prostate Cancer Canada, Movember Rising Star Award
"Intraductal Carcinoma of the Prostate : Imaging Mass Spectrometry for an in Situ Prognostic Oriented Characterization"
2015-2017 (PI) Prostate Cancer Canada, Movember Discovery Grant
"Adaptation of inelastic scattering detection technology for label-free molecular imaging to improve the reliability of prostatic biopsies"
Awards and prizes
2014 Junior Scientist Award, Canadian Association of Pathologists
2009 Dr Donald Rix Award, Canadian Association of Pathologists
2008 Dutkevich Memorial Trust award, Université Laval
2007 Dr Donald W. Penner award, Canadian Association of Pathologists
Prognostic associations of histological and tissue markers in prostate cancer
First axis : Intraductal Carcinoma of the Prostate
Intraductal carcinoma is an aggressive variant of prostate cancer. As the relative survival associated with prostate cancer is over 90% even after 10 years of follow-up, about 30% of men with intraductal carcinoma of the prostate experience recurrence which will eventually lead to death.
Our research is aimed at characterizing this disease histologically and prognostically, as well as in terms of response to treatment.
Second axis : Raman spectroscopy of prostate cancer
For many reasons, the diagnosis of prostate cancer relies on a random sampling of the prostate. As of today, this technique remains the best one to identify men with prostate cancer, but it is associated with approximately 30% of false negatives. Accordingly, the diagnosis of prostate cancer will first be missed in 30% of men who undergo biopsies.
Raman spectroscopy is a laser-based technique relying on the reflection of light on matter to identify its content. Since the reflection of light is specific to the content of tissue, it is possible to perform diagnosis with this technique. In collaboration with Pr Frédéric Leblond’s team, we are developing Raman spectroscopy diagnostic tools specific to prostate cancer.
Kelly Aubertin (Chercheure postdoctorale, firstname.lastname@example.org)
Nazim Benzerdjeb (Stagiaire postdoctoral, email@example.com)
Mirela Birlea (Assistante de recherche, firstname.lastname@example.org)
Lucresse Fossouo (MSc., email@example.com)
Andrée-Anne Grosset (Chercheure postdoctorale, firstname.lastname@example.org)
Mame Kany Diop (MSc., email@example.com)
Assia Ait Slimane (MSc., firstname.lastname@example.org)
Vincent Quoc-Huy Trinh (MSc., email@example.com)
Boutros, P. C., et al. (2015). "Spatial genomic heterogeneity within localized, multifocal prostate cancer." Nat Genet.
Fraser, M., et al. (2017). "Genomic hallmarks of localized, non-indolent prostate cancer." Nature 541(7637): 359-364.
Trudel, D., et al. (2014). "Visual and automated assessment of matrix metalloproteinase-14 tissue expression for the evaluation of ovarian cancer prognosis." Mod Pathol 27(10): 1394-1404.
Trudel, D., et al. (2014). "Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort." Eur J Cancer 50(9): 1610-1616.
Trudel, D., et al. (2003). "Significance of MMP-2 expression in prostate cancer: an immunohistochemical study." Cancer Res 63(23): 8511-8515.
Trudel, D., et al. (2013). "A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer." Gynecol Oncol 131(2): 357-361.
Trudel, D., et al. (2013). "4FISH-IF, a four-color dual-gene FISH combined with p63 immunofluorescence to evaluate NKX3.1 and MYC status in prostate cancer." J Histochem Cytochem 61(7): 500-509..